- Parenteral nutrition-associated cholestasis (PNAC) refers to a serious liver complication in preterm infants who are being administrated prolonged intravenous nutrition. Parenteral nutrition is defined as lifesaving intervention for many preterm infant’s other neonates suffering from severe illness
- The demand for Parenteral Nutrition-Associated Cholestasis Treatment is significantly driven by the increasing incidence of PNAC in neonates and patients requiring prolonged parenteral nutrition, heightened awareness among healthcare providers, advancements in lipid emulsions, and improved diagnostic and monitoring technologies
- North America is expected to dominate the Global Parenteral Nutrition-Associated Cholestasis Treatment market with a share of 36.4%, owing to its advanced neonatal and pediatric care infrastructure, high awareness among healthcare professionals, and strong presence of leading pharmaceutical and nutrition companies
- Asia-Pacific is projected to be the fastest-growing region in the Global Parenteral Nutrition-Associated Cholestasis Treatment market during the forecast period, driven by expanding healthcare access, increasing investments in neonatal care, and rising awareness of parenteral nutrition-related complications
- The Lipid Injectable Emulsion segment is anticipated to lead the market with a share of 34.5%, due to its essential role in minimizing cholestasis risk during long-term parenteral nutrition therapy. While emerging lipid formulations and novel treatment strategies are under development, traditional lipid emulsions remain the standard of care due to their proven efficacy, cost-effectiveness, and familiarity among clinicians
